ViroGates

Abonnér på pressemeddelelser

Følg

Abonner på pressemeddelelser fra ViroGates

Abonner på alle pressemeddelelser fra ViroGates ved at registrere din e-mail nedenfor. Det er ligeså let at melde fra igen.

ViroGates is an international medtech company developing and marketing prognostics products to improve patient care, reduce healthcare costs and empower clinical staff in the healthcare sector. Based on more than 600 clinical trials and studies, ViroGates’ suPARnostic® product range supports hospital professionals in making clinical decisions on hospitalization or discharge of acute care patients as well as detecting and assessing the severity of cardiovascular diseases, type 2 diabetes, cancer, etc. suPARnostic® TurbiLatex is available on Roche Diagnostics’ Cobas instruments and ViroGates works with partners to develop solutions for other platforms. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Germany, Spain, and France, while distributors serve other markets. www.virogates.com

ViroGates
Banevænget 13
3460 Birkerød
www.virogates.com

Selskabsmeddelelser

113

ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 20232.5.2024 11:20:15 CEST | ViroGates | Interim information

COMPANY ANNOUNCEMENT - No. 5-2024 - 02 May 2024– Inside information BIRKERØD, DENMARK – ViroGates A/S announces its Interim Report for the period 1 January 2024 – 31 March 2024, as approved today by the company’s Board of Directors. In Q1, 2024, ViroGates’ revenue was TDKK 1,199, representing an increase of 14% compared to the same period in the previous year (TDKK 1,049). Despite the slight increase in revenue compared to last year, sales remain at a low level due to less activity among hospital customers. ViroGates continues to push for the implementation of suPARnostic® with these customers by promoting both the triage and sepsis application while also working to get traction among health clinics in general health and longevity. ViroGates reports 15 recurring customers by the end of Q1, 2024 (as of 31 March 2024), representing a decrease of 3 customers compared to Q1, 2023 (18 recurring customers). Of the 15 customers reported, 9 are using suPARnostic® in clinical routine and 6 are

2 vedhæftninger

Resolutions from the Annual General Meeting of ViroGates A/S25.4.2024 20:29:07 CEST | ViroGates | Resolutions of annual general meeting

COMPANY ANNOUNCEMENT - No. 4-2024 - 25 April 2024 BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today held its annual general meeting at the company headquarters Banevænget 13, 3460 Birkerød, Denmark. Reference is made to company announcement no. 02-2024 of 10 April 2024, setting out the agenda and complete proposals. The following resolutions were passed: Attorney-at-law Jens Folker-Bruun was elected chairman of the general meeting. The general meeting approved the board’s report on the company’s business for 2023. The annual report was approved. It was resolved to transfer the loss for the financial year 2023 of DKK -12,096,105 to the following year. An indicative vote approved the remuneration report. Patrik Dahlen, Lars Kongsbak and Valérie Soulier were re-elected as board members. It was resolved that the annual remuneration fee for the board’s work in 202

1 vedhæftning

ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA15.4.2024 18:36:24 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 03-2024 – Inside information - 15 April 2024 BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces the outcome of today’s meeting with the Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). As previously announced in Company announcement 12-2023, ViroGates is supported by Sobi® to gain market clearance/approval for suPARnostic® TurbiLatex to be available in the US market to identify patients who may be eligible for treatment with Sobi’s drug Kineret®. ViroGates has filed for a consultation with the CDRH division of the FDA under the Q-Submission scheme. ViroGates sought advice from the FDA regarding several aspects of its analytical method and clinical data packages. FDA has certain requirements for data supplied to support that products are reliable, reproducible, and consistent, which d

1 vedhæftning

ViroGates gives notice to convene the Annual General Meeting on 25 April 202410.4.2024 13:46:40 CEST | ViroGates | Notice to convene annual general meeting

COMPANY ANNOUNCEMENT - No. 2-2024 – Notice to convene the annual general assembly - 10 April 2024 BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, hereby convenes the Annual General Meeting on Thursday, 25 April 2024, at 5:00 pm. The meeting will be at the company's address at Banevænget 13, 3460 Birkerød. The agenda, full proposals, and registration details can be found in the attached document and on the company’s website. For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogates.com Certified Advisor: Västra Hamnen Corporate Finance Per Lönn Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se About ViroGates ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce h

1 vedhæftning

ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage21.3.2024 12:26:30 CET | ViroGates | Annual financial report

COMPANY ANNOUNCEMENT - No. 01-2024 – Inside information - 21 March 2024 BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2023, as approved today by the company’s Board of Directors. 2023 was a challenging year for ViroGates. The company had to adapt from a period where suPARnostic® was used primarily to help manage COVID-19 patients, and the onboarding of customers onto the triage solution appeared to be much more difficult than expected. Revenue declined by 45% compared to 2022 results. To ensure a higher correlation between revenue levels and ViroGates’ reporting of recurring customers, a new measure of recurring customers was introduced for the second half of 2023. On that basis, ViroGates reports 17 recurring customers in clinical routine and research by the end of 2023. In 2023, we saw continu

2 vedhæftninger

Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S21.12.2023 16:25:46 CET | ViroGates | Major shareholder announcements

COMPANY ANNOUNCEMENT - No. 27-2023 – Information about majority shareholder - 21 December 2023 BIRKERØD, DENMARK - ViroGates A/S (“VIRO”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that the majority shareholder of the company, N. P. Louis-Hansen ApS, has subscribed for 799,075 shares in the Company as part of the recently completed rights emission, cf. company announcement no. 19-2023 from ViroGates. The shares were allocated on 19th December 2023 and have been transferred to the permanent ISIN as of today. N. P. Louis-Hansen ApS is the majority shareholder with post-subscription holdings of less than 25% of the share capital and more than 25% of the voting rights in ViroGates A/S. The announcement can be found at https://www.virogates.com/investor/announcements. For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogat

1 vedhæftning

ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 1921.12.2023 16:24:31 CET | ViroGates | Managers' Transactions

COMPANY ANNOUNCEMENT - No. 26-2023 - 21 December 2023 BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. Under the EU’s Market Abuse Regulation art. 19, ViroGates A/S must notify the Danish Financial Supervisory Authority and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading ViroGates shares if the statutory threshold of 20,000 EUR limit is exceeded. ViroGates hereby notifies and submits the following transactions of shares in ViroGates: Jakob Knudsen, Chief executive officer of ViroGates A/S, exercised subscription rights to shares and received 102,388 shares on 19 December 2023. The subscription for shares was related to the recently completed rights emiss

3 vedhæftninger

ViroGates publishes its financial calendar for 202421.12.2023 16:22:57 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 25-2023 - 21 December 2023 BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today publishes the financial calendar for 2024 with the following key dates: 21 March 2024 Annual Report 2023 4 April 2024 Deadline for submission of business to be transacted at the 2024 Annual General Meeting 25 April 2024 Annual General Meeting 2 May 2024 Interim Report Q1 2024 15 August 2024 Interim Report H1 2024 7 November 2024 Interim Report Q1-Q3 2024 The interim and annual financial reports will be available on ViroGates’ website (www.virogates.com) immediately after release. ViroGates encourages all shareholders to sign up to receive relevant shareholder information at its shareholder portal (www.virogates.com/shareholder-portal). Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if recei

1 vedhæftning

ViroGates announces financial guidance for 202421.12.2023 16:20:42 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 24-2023 – Inside information - 21 December 2023 BIRKERØD, DENMARK - ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its financial guidance for 2024. ViroGates expects full-year revenue between DKK 8 and 10 million in 2024 and an EBIT of DKK -10 to -12 million in 2024. Due to the uncertainty surrounding both sales to the acute care segment, underlined by adjustments made to the financial guidance for 2023 during the year, as well as the effects of ViroGates’ recent entry into a new customer segment in longevity and general health management, ViroGates will pause its guidance to the market on becoming cash flow positive. Jakob Knudsen, CEO of ViroGates, says: “We have had a difficult 2023 with respect to sales, and we did not perform to the extent we wanted. Unfortunately, this led to revisions to our financial guidan

1 vedhæftning

ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered19.12.2023 16:03:14 CET | ViroGates | Total number of voting rights and capital

COMPANY ANNOUNCEMENT - No. 23-2023 - 19 December 2023 BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”) announces that the capital raise of approximately DKK 13.9 million has been completed. The issue of 3,097,047 new shares at a price of DKK 4.5 per share has been registered with the Danish Business Authority. Prior to the increase, the Company’s share capital amounted to DKK 3,350,507, consisting of 3,350,507 shares of nominally DKK 1 each. After the nominal increase of DKK 3,097,047, the Company’s share capital now amounts to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each. The change in share capital is reflected in the Company’s articles of association available on the Company’s website. ViroGates further expects that the first day of trading of the new shares on Nasdaq First North Growth Market Denmark is 21 December 2023. For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogates.com C

1 vedhæftning

ViroGates announces the outcome of its rights issue15.12.2023 10:58:37 CET | ViroGates | Total number of voting rights and capital

COMPANY ANNOUNCEMENT - No. 22-2023 - 15 December 2023 MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. BIRKERØD, DENMARK – ViroGates A/S (“ViroGates or the “Company”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces the outcome of its rights issue of shares of up to approximately DKK 15.1 million, for which the subscription period ended 13 December 2023. Shares corresponding to approximately 92% of the issue were subscribed for, and ViroGates thus raises approximately DKK 13.9 million before deduction of costs related to the issue. Outcome The “Maximum Offer” was comprised of 3,350,507 shares. The outcome of the rights issue of shares shows that 2,559,722 shares

1 vedhæftning

ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 197.12.2023 16:12:32 CET | ViroGates | Managers' Transactions

COMPANY ANNOUNCEMENT - No. 21-2023 - 7th December 2023 MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Under the EU’s Market Abuse Regulation article 19, ViroGates A/S must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on the trading of ViroGates shares. ViroGates hereby notifies and submits the following transaction of shares in ViroGates: Jakob Knudsen, Chief executive officer of ViroGates A/S, bought subscription rights to shares in ViroGates on 5th and 6th December 2023. The subscription rights are related to the ongoing Rights emission in ViroGates. The Form related to the transaction is attached. The announcement can be found at https://www.virogates.co

2 vedhæftninger

The subscription period in ViroGates’ rights issue begins today30.11.2023 13:07:05 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 20-2023 - 30 November 2023 MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. BIRKERØD, DENMARK - Today, November 30, 2023, the subscription period in ViroGates A/S’ (“ViroGates” or the “Company”) rights issue of maximum DKK 15,077,282 before issue costs (the “Offering”) with pre-emptive rights for the Company's existing shareholders ("Existing Shareholders") begins. The Offering is covered by subscription commitments up to DKK 7,309,274, corresponding to approximately 48 percent of the Offering, from three existing shareholders and representatives from the Board of Directors and management. The Offering was approved at the Extraordinary General Meeting held on November 24, 2023. Background for the Offering and use of proceeds ViroGates has

1 vedhæftning

Resolutions from the Extraordinary General Meeting of ViroGates A/S24.11.2023 10:45:46 CET | ViroGates | Decisions of general meeting

COMPANY ANNOUNCEMENT - No. 19-2023 - 24 November 2023 BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today held an extraordinary general meeting at the company headquarters at Banevænget 13, 3460 Birkerød, Denmark. Reference is made to company announcement no. 18-2023 of 9 November 2023, setting out the agenda and complete proposals. The following resolutions were passed: Attorney-at-law Lars Lüthjohan was elected chairman of the general meeting. The proposal for a new article 2.4 was approved. The approval of the new article 2.4 provides the Board of Directors with an authorization to increase the Company’s share capital through issuance of new shares with up to nominal DKK 3,350,507 with pre-emptive rights for existing shareholders. The authorization corresponds to the Maximum Offer of the recently announced rights offering, cf. company announcement no. 17-202

1 vedhæftning

ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 20239.11.2023 12:11:18 CET | ViroGates | Notice to general meeting

COMPANY ANNOUNCEMENT - No. 18-2023 - Notice to convene an Extraordinary General Meeting - 09 November 2023 BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, hereby convenes an Extraordinary General Meeting on 24 November 2023 at 10:00. The meeting will be at the company's address at Banevænget 13, 3460 Birkerød. The agenda, full proposals, and registration details can be found in the attached document. For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogates.com Certified Advisor: Västra Hamnen Corporate Finance Per Lönn Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se About ViroGates ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empo

4 vedhæftninger

ViroGates announces an offering of new shares with pre-emptive rights for existing shareholders9.11.2023 12:08:17 CET | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 17-2023 - Inside information - 09 November 2023 MAY NOT BE PUBLISHED, DISTRIBUTED OR DELIVERED FULLY OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, UNITED KINGDOM, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. BIRKERØD, DENMARK - The Board of Directors of ViroGates A/S ("ViroGates" or "the Company") has today decided to initiate a rights offering process. The rights offering is subject to the shareholders approving an authorisation to be adopted in the Company’s articles of association to the Board of Directors to increase the Company's share capital by minimum nominal DKK 1,624,283 (“the Minimum Offer”) corresponding to 1,624,283 new shares and up to a nominal DKK 3,350,507 (“the Maximum Offer”) corresponding to 3,350,507 new shares, each with a nominal value of DKK 1 (the “Offering”). The subscription price will be DKK 4.5 per share (the "Subscript

1 vedhæftning

ViroGates announces its Interim Report for Q1-Q3, 2023: Revenue for the first nine months (Q1-Q3, 2023) was affected by a rough start to the year, despite Q3 itself represented Year-on-Year growth of 40%9.11.2023 12:05:30 CET | ViroGates | Interim information

COMPANY ANNOUNCEMENT - No. 16-2023 - Inside information - 09 November 2023 BIRKERØD, DENMARK – ViroGates A/S announces its Interim Report for the period 1 January 2023 – 30 September 2023, as approved today by the company’s Board of Directors. In Q1-Q3, 2023, ViroGates’ revenue totaled TDKK 4,780, representing a decline of 39% compared to the same period in 2022 (TDKK 7,882). The third quarter itself represented a Year-on-Year growth of 40% (from 1,587 in Q3, 2022 to TDKK 2,228 in Q3, 2023). Despite this growth and the upward trend in revenue, ViroGates continues to operate in an uncertain environment, where the conversion of the previous COVID-19 customers is still challenging, and many customer activities need to be restarted. ViroGates reports 16 recurring customers by the end of Q3, 2023 (as of 30 September 2023), representing a slight increase since the end of H1, 2023. Of the 16 customers, 9 are using suPARnostic® in clinical routine, and 7 are using suPARnostic® for research pur

2 vedhæftninger

ViroGates announces positive results from a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today at the European Shock Conference in Vienna, Austria22.9.2023 13:59:23 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 15-2023 – Inside information - 22 September 2023 BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces positive results of a randomized controlled clinical trial on suPAR-guided antibiotic treatment in sepsis presented today, Friday the 22nd of September 2023, at the European Shock Conference in Vienna, Austria by Dr Maria Adami from the Hellenic Sepsis Group. Sepsis is a deadly disease and is estimated to account for around 11 million deaths annually. Early treatment is pivotal but often not initiated, as early diagnosis is missed. Current guidelines suggest that patients admitted to the emergency department (ED) should be treated for sepsis if they have at least two of three signs of risk for sepsis (2 or 3 points in the qSOFA score system). However, if a patient has only one sign of risk, treatment is often delayed to limit the u

1 vedhæftning

ViroGates announces its half-year report for H1, 2023: Revenue is still negatively affected by lower-than-expected sales to clinical routine customers17.8.2023 11:38:51 CEST | ViroGates | Interim information

COMPANY ANNOUNCEMENT - No. 14-2023 – Inside information - 17 August 2023 BIRKERØD, DENMARK – ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its half-year report for the period 1 January 2023 – 30 June 2023, as approved today by the company’s Board of Directors. In H1, 2023, ViroGates’ revenue was TDKK 2,553, representing a decline of 59% compared to the same period in 2022 (TDKK 6,295). The decrease is due to a more challenging-than-expected conversion of COVID-19 hospitals into hospitals using suPARnostic® in the ED for triage as well as lower activity levels from previous clinical routine customers. As notified in the previous quarterly report (Q1, 2023), ViroGates’ management and the Board of Directors have worked on a revised measure of the number of customers more strongly correlated with current revenue levels. The new measure builds upon the previous measure and re

1 vedhæftning

ViroGates announces its half-year report for H1, 2023 on 17th August 2023 and will host a webcast for investors11.8.2023 12:11:59 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT - No. 13-2023 - 11 August 2023 BIRKERØD, DENMARK – ViroGates A/S inform that it will announce its half-year report covering 1 January 2023 – 30 June 2023 on Thursday 17th August 2023. The report will be released immediately after the Board of Directors' approval on the same day. ViroGates will host a webinar for investors on Friday 18th August at 10:00. The meeting will be an online interactive meeting with an initial presentation of the results from the H1, 2023 report and a subsequent Q&A session. Sign up for the webinar here. When the report is announced, it will be available on the Investor webpage. For further information, please contact: ViroGates A/S: CEO, Jakob Knudsen Tel. (+45) 2226 1355, email: jk@virogates.com Certified Advisor: Västra Hamnen Corporate Finance Per Lönn Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se About ViroGates ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARn

1 vedhæftning

Sidste
>>

ViroGates
Banevænget 13
3460 Birkerød
www.virogates.com